Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07532369 · ClinicalTrials.gov registry record
Occlutech AFR Fontan Study
A clinical trial, sponsored by Occlutech International AB.
- Not yet
- Registry status
- 25
- Enrollment target
NCT07532369: Clinical Trial study, sponsored by Occlutech International AB.
NCT07532369 is a clinical trial that has not yet begun recruiting, run by Occlutech International AB. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07532369 has not yet begun recruiting, sponsored by Occlutech International AB.
- NOT YET RECRUITING
- Registry status
- 25 participants
- Enrollment target
Study Summary
The goal of this observational clinical study look at the safety and effectiveness of the Occlutech Atrial Flow Regulator in the treatment of patients with failing Fontan circulation. This study will consist of a case series of congenital patients with Fontan failure who have been treated with an Occlutech AFR under the FDA's Expanded Access process. The scope of this study is to gain clinical experience on the Occlutech AFR in Fontan failure patients. Cases in this study will be evaluated to evaluate the safety and effectiveness of the device. The objective of this study is to evaluate the Occlutech AFR with respect to device safety and shunt patency at 1 year. Shunt patency defined by persistent right to left shunt assessed by echocardiography at 1-year post-procedure.
Primary Outcome
Shunt patency defined by persistent right to left shunt assessed by echocardiography at 1-year post-procedure.
Interventions
- DEVICE Occlutech Atrial Flow Regulator Retrospective Data Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2026-09 |
What is known before NCT07532369 opens enrollment
NCT07532369 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Occlutech Atrial Flow Regulator Retrospective Data Collection is the first listed.
NCT07532369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07532369 about?
NCT07532369 is a clinical study titled "Occlutech AFR Fontan Study". The goal of this observational clinical study look at the safety and effectiveness of the Occlutech Atrial Flow Regulator in the treatment of patients with failing Fontan circulation. This study will consist of a case series of congenital patients with Fontan failure who have been treated with an Oc...
What is the current status of trial NCT07532369?
This trial is currently not yet recruiting. The enrollment target is 25 participants. The study started on 2026-05-01. Estimated completion is 2026-09.
What interventions are being tested in trial NCT07532369?
The interventions under investigation include: Occlutech Atrial Flow Regulator Retrospective Data Collection (DEVICE).
Who is sponsoring clinical trial NCT07532369?
This trial is sponsored by Occlutech International AB, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI